Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.

BACKGROUND & AIMS Given the organ shortage for liver transplantation (LT) and the limitations of the current morphology-based selection criteria, improved criteria are needed to achieve the maximum benefit of LT for hepatocellular carcinoma (HCC). We hypothesized that a combination of biological markers may better predict the prognosis than the Milan criteria. METHODS HCC patients (n=123) with preoperative data on serum alpha-fetoprotein (AFP) levels and (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) positivity underwent live-donor LT between January 2003 and December 2009. The cut-off values for serum AFP levels (200 ng/ml) and (18)F-FDG PET positivity (1.10) for tumor recurrence were determined by c-statistics using receiver operating characteristic curves. Univariate and multivariate analyses with preoperative variables were performed to find pre-transplant prognostic factors. Disease-free survival rates and overall survival rates were analysed with regard to serum AFP levels and (18)F-FDG PET positivity. RESULTS The 5-year disease-free survival rates and overall survival rates were 80.3% and 81.6% respectively. (18)F-FDG PET positivity (hazard ratio (HR) 9.766, 95% CI 3.557-26.816; p<0.001) and serum AFP level (HR 6.234, 95% CI 2.643-14.707; p<0.001) were the only significant pre-transplant prognostic factors in the multivariate analysis; tumor number and size were not significant. A combination of criteria showed that the biologically high-risk group (AFP level ⩾200 ng/ml and PET-positive) had an HR of 29.069 (95% CI 8.797-96.053; p<0.001) compared with the double-negative group. Use of the Milan criteria yielded an HR of 1.351 (95% CI 0.500-3.652; p=0.553). CONCLUSIONS The combination of the serum AFP level and (18)F-FDG PET data predicted better outcomes than those using the Milan criteria, improving objectivity when adult-to-adult living donor LT is contemplated.

[1]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[2]  S. Uemoto,et al.  Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  H. Bismuth,et al.  Liver Transplantation for Hepatocellular Carcinoma , 1999, Seminars in liver disease.

[4]  W. Hop,et al.  Liver transplantation for unresectable hepatocellular carcinoma in normal livers. , 2012, Journal of hepatology.

[5]  Y. Cho,et al.  The role of 18F‐FDG‐PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients , 2006 .

[6]  Y. Cho,et al.  The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[7]  P. Morel,et al.  The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. , 2011, Journal of hepatology.

[8]  G. Ioannou,et al.  Serum alpha‐fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[10]  M. Sherman,et al.  Outcome of Small (10–20 mm) Arterial Phase-Enhancing Nodules Seen on Triphasic Liver CT in Patients with Cirrhosis or Chronic Liver Disease , 2005, The American Journal of Gastroenterology.

[11]  S. Sell.  Alpha-Fetoprotein, Stem Cells and Cancer: How Study of the Production of Alpha-Fetoprotein during Chemical Hepatocarcinogenesis Led to Reaffirmation of the Stem Cell Theory of Cancer , 2008, Tumor Biology.

[12]  O. Dirsch,et al.  Liver Transplantation for Hepatocellular Carcinoma in Cirrhosis: Is Clinical Tumor Classification before Transplantation Realistic? , 2005, Transplantation.

[13]  T. Schiano,et al.  Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up‐to‐seven criteria , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  Shankar Vallabhajosula,et al.  (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. , 2007, Seminars in nuclear medicine.

[15]  L. Mariani,et al.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. , 2009, The Lancet. Oncology.

[16]  M. Reddy,et al.  Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. , 2007, Transplantation.

[17]  Hyun Woo Kwon,et al.  Prediction of Tumor Recurrence by 18F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma , 2009, Journal of Nuclear Medicine.

[18]  J. Steenbeck,et al.  18F‐FDG‐Uptake of Hepatocellular Carcinoma on PET Predicts Microvascular Tumor Invasion in Liver Transplant Patients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  T. Livraghi,et al.  Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  Liver transplantation for hepatocellular carcinoma: the Japanese experience , 2010, Journal of hepato-biliary-pancreatic sciences.

[21]  Patrick M M Bossuyt,et al.  Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. , 2012, The Lancet. Oncology.

[22]  F. Roudot-thoraval,et al.  Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. , 2012, Gastroenterology.

[23]  V. Mazzaferro.  Results of liver transplantation: With or without milan criteria? , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  A. Dhillon,et al.  Liver Transplantation and Recurrent Hepatocellular Carcinoma: Predictive Value of Nodule Size in a Retrospective and Explant Study , 2006, Transplantation.

[25]  D. Harnois.  Reassessing Selection Criteria Prior to Liver Transplantation for Hepatocellular Carcinoma Utilizing the Scientific Registry of Transplant Recipients Database , 2009 .

[26]  Ann Harper,et al.  Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[27]  M. Guba,et al.  Liver Transplantation for Advanced Hepatocellular Carcinoma Using Poor Tumor Differentiation on Biopsy as an Exclusion Criterion , 2011, Annals of surgery.

[28]  A. Venook,et al.  Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival , 2001, Hepatology.

[29]  K. Lee,et al.  Liver Transplantation for Hepatocellular Carcinoma in Patients Who Do Not Meet the Milan Criteria , 2007, Digestive Diseases.